Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018085198) 5-HALOURACIL-MODIFIED MICRORNAS AND THEIR USE IN THE TREATMENT OF CANCER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/085198 International Application No.: PCT/US2017/059011
Publication Date: 11.05.2018 International Filing Date: 30.10.2017
IPC:
A61K 31/7105 (2006.01) ,A61K 45/06 (2006.01) ,A61K 48/00 (2006.01) ,A61N 5/10 (2006.01) ,A61P 35/00 (2006.01) ,C07H 21/02 (2006.01)
[IPC code unknown for A61K 31/7105][IPC code unknown for A61K 45/06][IPC code unknown for A61K 48][IPC code unknown for A61N 5/10][IPC code unknown for A61P 35][IPC code unknown for C07H 21/02]
Applicants:
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK [US/US]; 35 State Street Albany, New York 12207, US
Inventors:
JU, Jingfang; US
Agent:
GROLZ, Edward W.; US
Priority Data:
62/415,74001.11.2016US
62/422,29815.11.2016US
62/464,49128.02.2017US
Title (EN) 5-HALOURACIL-MODIFIED MICRORNAS AND THEIR USE IN THE TREATMENT OF CANCER
(FR) MICROARN MODIFIÉS PAR 5-HALOGÉNO-URACILE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
Abstract:
(EN) The present disclosure provides nucleic acid compositions that incorporate one or more halouracil molecules. More specifically, the present disclosure reveals that the replacement of uracil nucleotides within a microRNA nucleotide sequence with a 5-halouracil increases the ability of the micro-RNA to inhibit cancer progression and tumorigenesis. As such, the present disclosure provides various nucleic acid (e.g., microRNA) compositions having 5-halouracil molecules incorporated in their nucleic acid sequences and methods for using the same. The present disclosure further provides pharmaceutical compositions (e.g., formulations) comprising the modified nucleic acid compositions, and methods for treating cancers, such as colorectal, pancreatic and lung cancer.
(FR) La présente invention concerne des compositions d’acide nucléique qui incorporent une ou plusieurs molécules d’halogéno-uracile. Plus spécifiquement, la présente invention montre que le remplacement de nucléotides d’uracile dans une séquence nucléotidique de microARN avec un 5-halogéno-uracile augmente la capacité du microARN à inhiber la progression du cancer et la tumorigenèse. Par conséquent, la présente invention concerne différentes compositions d’acide nucléique (par exemple, des microARN) comportant des molécules de 5-halogéno-uracile incorporées dans leurs séquences d’acide nucléique et des procédés d’utilisation de celles-ci. La présente invention concerne en outre des compositions pharmaceutiques (par exemple, des formulations) comprenant les compositions d’acides nucléiques modifiées, et des procédés de traitement de cancers, tels que le cancer colorectal, du pacréas et du poumon.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)